Skip to main navigation Skip to search Skip to main content

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma

  • Sundar Jagannath
  • , Bart Barlogie
  • , James R. Berenson
  • , David S. Siegel
  • , David Irwin
  • , Paul G. Richardson
  • , Ruben Niesvizky
  • , Raymond Alexanian
  • , Steven A. Limentani
  • , Melissa Alsina
  • , Dixie Lee Esseltine
  • , Kenneth C. Anderson
  • Saint Vincent Catholic Medical Centers
  • University of Arkansas for Medical Sciences
  • Institute for Myeloma Bone Cancer Research
  • Alta Bates Compreh. Cancer Center
  • Dana-Farber Cancer Institute
  • Cornell University
  • University of Texas MD Anderson Cancer Center
  • Carolinas Hematology/Oncology Associates
  • Moffitt Cancer Center
  • Takeda Pharmaceutical Company Limited

Research output: Contribution to journal › Article › peer-review

93 Scopus citations

Abstract

The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1.0 and 1.3 mg/m2), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated survival analyses after prolonged follow-up (median >5 years). One- and 5-year survival rates were 82% and 32%, respectively, in the 1.0 mg/m 2 group (n = 28), and 81% and 45%, respectively, in the 1.3 mg/m 2 group (n = 26). Notable survival, response, and time-to-progression data suggest that a bortezomib starting dose of 1.3 mg/m2 is preferred. If bortezomib dose reduction is required, the 1.0 mg/m2 dose still offers patients a substantial survival benefit.

Original languageEnglish
Pages (from-to)537-540
Number of pages4
JournalBritish Journal of Haematology
Volume143
Issue number4
DOIs
StatePublished - Nov 2008

Keywords

  • Bortezomib
  • Multiple myeloma
  • Refractory
  • Relapsed
  • Survival

Fingerprint

Dive into the research topics of 'Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma'. Together they form a unique fingerprint.

Cite this